Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | LPL | P06858 | 5/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59736 | 0.88 | ATM (0.49) | ALDH1A1HIF1ALPLLIPGVCAM1 | |
| SCHEMBL190588 | 0.83 | TDP1 (0.54) | ALDH1A1LPLLIPGLMNAMAPT | |
| SCHEMBL4550135 | 0.83 | ALDH1A1 (0.47) | ALDH1A1LPLLIPGLMNAMAPT | |
| SCHEMBL14158127 | 0.82 | ALDH1A1 (0.56) | ALDH1A1HIF1ALPLLIPGLMNA | |
| SCHEMBL28452550 | 0.82 | CA1 (0.40) | ALDH1A1HIF1ALPLLIPGCA1 | |
| SCHEMBL23926487 | 0.82 | VCAM1 (0.47) | ALDH1A1LPLLIPGVCAM1LMNA | |
| SCHEMBL23830122 | 0.82 | ALDH1A1 (0.40) | ALDH1A1HIF1ALPLLIPGVCAM1 | |
| SCHEMBL30955191 | 0.82 | VCAM1 (0.47) | ALDH1A1LPLLIPGVCAM1LMNA | |
| SCHEMBL5259857 | 0.81 | MAPT (0.48) | ALDH1A1HIF1AVCAM1LMNAHTT | |
| SCHEMBL29867167 | 0.81 | ALDH1A1 (0.39) | ALDH1A1HIF1ALPLLIPGLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519409-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING HIV INFECTION | GILEAD SCIENCES INC (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230406838-A1 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-21 | — | — | US | disclosed |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| EP-4126839-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | Dong-A ST Co., Ltd. (KR) | 2023-02-08 | — | — | EP | disclosed |
| CN-115397818-A | Aminopyrimidine derivatives and their use as modulators of arene receptors | 东亚ST株式会社 | 2022-11-25 | — | — | CN | disclosed |
| US-20220267353-A1 | PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-25 | — | — | US | disclosed |
| WO-2022067063-A1 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-08 | — | — | US | disclosed |
| US-8598174-B2 | Pyridazinones, method of making, and method of use thereof | GENETECH, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| WO-2013159064-A1 | BENZOTHIAZOL- 6 -YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2365970-A1 | Pyridazinones and their use as btk inhibitors | CGI Pharmaceuticals, Inc. (US) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010056875-A1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056875-A1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | ALDH1A1 2433/4885HIF1A 2362/4885LPL 2629/4885 |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, LCK | ALDH1A1 3488/4885HIF1A 4846/4885LPL 1508/4885 |
| US-20230406838-A1 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | ALDH1A1 4014/4885HIF1A 2322/4885LPL 3126/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | ALDH1A1 355/4885HIF1A 4094/4885LPL 895/4885 |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | ALDH1A1 240/4885HIF1A 157/4885LPL 2250/4885 |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | ALDH1A1 2433/4885HIF1A 2362/4885LPL 2629/4885 |
| US-20220267353-A1 | PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PPIB, RHEB | ALDH1A1 2433/4885HIF1A 2362/4885LPL 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.